Skye Bioscience (SKYE) Return on Invested Capital (2018 - 2026)

Skye Bioscience (SKYE) has reported Return on Invested Capital for 9 consecutive years, with 0.12% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Invested Capital fell 9.0% year-over-year to 0.12%; the TTM figure through Mar 2026 stood at 0.12% (down 9.0% YoY), while the FY2024 annual figure was 0.1%, down 3.0% from the prior year.
• Return on Invested Capital declined to 0.12% in Q1 2026 per SKYE's latest filing, from 0.09% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.01% in Q3 2024 and bottomed at 0.2% in Q2 2022.
• Historically, Return on Invested Capital has averaged 0.06% across 5 years, with a median of 0.03% in 2023.
• Annual changes were most pronounced in 2022 — Return on Invested Capital soared 53 bps — and 2026, when it dropped 9 bps.
• Skye Bioscience's Return on Invested Capital stood at 0.05% in 2022, then soared by 60 bps to 0.02% in 2023, then retreated by 12 bps to 0.02% in 2024, then slumped by 296 bps to 0.09% in 2025, then slumped by 37 bps to 0.12% in 2026.
• Business Quant data shows SKYE's Return on Invested Capital at 0.12% in Q1 2026, 0.09% in Q4 2025, and 0.08% in Q3 2025.